Piper Jaffray analyst Brooks West views the FDA's complete response letter to Novartis (NVS) for its biosimilar application to Amgen's (AMGN) Neulasta as a positive for Insulet (PODD). It now looks like Amgen won't face a biosimilar to Neulasta until mid-2017 at the earliest versus prior Street expectations for Q4 of 2016, West tells investors in a research note. Insulet manufactures Amgen's drug delivery device and one of the primary bear theses on the company is that pending biosimilar competition will put its drug delivery revenue from its custom OnPro Kit at risk, the analyst contends. He keeps an Overweight rating on Insulet with a $41 price target.